

1. Record Nr.	UNINA9910298270203321
Titolo	Biomarkers in Cancer // edited by Victor R. Preedy, Vinood B. Patel
Pubbl/distr/stampa	Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2015
ISBN	94-007-7681-0
Edizione	[1st ed. 2015.]
Descrizione fisica	1 online resource (180 illus., 134 illus. in color. eReference.)
Collana	Biomarkers in Disease: Methods, Discoveries and Applications, , 2542-3657
Disciplina	616.9940756
Soggetti	Cancer research Oncology Pharmacology Cancer Research Oncology Pharmacology/Toxicology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- Preface -- Series Preface -- Contents -- About the Editors -- Editorial Advisors -- Contributors -- Part I: General Aspects: Techniques and Overviews -- 1 OMICS for Tumor Biomarker Research -- Key Facts of OMICS Sciences -- Definitions of Words and Terms -- Introduction: A Role of OMICS in Cancer Biomarker Research -- An Analysis Pathway for Multiplex Biomarker Panels -- Transcriptome Profiling Approaches and Multiplexed Panels Based on mRNA Levels -- Proteomics: From MALDI-TOF Through Shotgun Techniques to Targeted Approach -- Metabolomics: A Promising New Direction for Biomarker Discovery -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Conclusion -- Summary Points -- References -- 2 Circulating Tumor Cells as Biomarkers in Cancer -- Key Facts About Circulating Tumor Cells (CTCs) -- Definition of Words and Terms -- Introduction to Circulating Tumor Cells -- Detection of CTCs by RT-PCR -- CTC Enrichment Technologies -- Enrichment by Physical Properties -- Cell Surface Marker-Based Enrichment -- Emerging Technologies -- Microfluidic Devices -- High-Definition CTC -- DEParray -- Positive Versus Negative Enrichment of CTCs --

Quantification of CTCs as a Predictor of Survival and a Marker of Therapy Response -- CTC Characterization and Monitoring Therapy Responses -- Concluding Remarks -- Summary Points -- References -- 3 Oncoproteomic Approaches to Cancer Marker Discovery: The Case of Colorectal Cancer -- Key Facts -- Definition of Words and Terms -- Introduction -- Colorectal Cancer -- Biomarkers in Cancer -- Why Proteomics? -- Proteomic Technologies -- Two-Dimensional Gel Electrophoresis -- Gel-Free Proteomics: Isotopic Labeling -- Label-Free Mass Spectrometry -- Detection of Post-Translational Modifications -- Early Detection Screening Technologies and Samples for CRC Biomarker Research.

Protein Biomarkers of Colon Cancer -- Carcinoembryonic Antigen -- Fecal Hemoglobin -- Potential Application of Proteomics to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 4 Cancer Cardiotoxicity and Cardiac Biomarkers -- Definition of Words and Terms -- Introduction -- Cardiotoxicity of Cancer Therapy -- Summary Points -- Key Facts of Cardiotoxicity -- Chemotherapeutic Agents -- Anthracycline -- Targeted Therapy -- Trastuzumab -- Inhibitors of Angiogenesis -- Summary Points -- Key Facts of Chemotherapeutic Agents -- Monitoring of Drug-Induced Cardiotoxicity -- Cardiac Imaging -- Serological Markers -- Summary Points -- Key Facts of Monitoring of Drug-Induced Cardiotoxicity -- Troponins -- Summary Points -- Key Facts of Troponin -- Natriuretic Peptides -- Summary Points -- Key Facts of Natriuretic Peptide -- Potential Application to Prognosis and Other Disease Conditions -- Summary Points -- Key Facts of Potential Application to Prognosis and Other Disease Conditions -- References -- 5 DNA Methylation as a Biomarker in Cancer -- Key Facts -- Key Facts of DNMT: DNA Methyltransferase -- Key Facts of CGIs: CpG Islands -- Key Facts of MBD Proteins: Methyl-CpG-Binding-Domain Proteins -- Definitions of Words and Terms -- Introduction -- DNA Methylation in Normal Cells -- Relationship Between CGI DNA Methylation and Transcriptional Repression -- DNA Methylation in Cancer Cells -- 5-Hydroxymethylcytosine and Its Derivatives in Cancer -- Long-Range Coordinated Disruptions in DNA Methylation -- CpG Island Methylator Phenotype -- Methods of Isolating DNA Methylation Biomarkers in Cancer -- DNA Methylation Changes in Early Tumorigenesis -- The Suitability of DNA Methylation Changes as Biomarkers -- DNA Methylation as Early Detection Biomarkers -- DNA Methylation Biomarkers for Prediction of Drug Sensitivity -- Future Perspectives. Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 6 Kallikreins as Biomarkers in Human Malignancies -- Key Facts on Kallikrein Family -- Definitions of Words and Terms -- Introduction -- KLK Family: A Rich Source of Cancer Biomarkers -- Prostate Cancer -- Prostate-Specific Antigen (PSA/KLK3): A Long-Used yet Disputed Biomarker for CaP Screening and Diagnosis -- PSA/KLK3: Applications in CaP Patients' Treatment Monitoring and Prediction of Clinical Outcome -- Emerging Biomarkers in Prostate Cancer from the Kallikrein Family: Can They Follow and/or Enrich the Success of PSA/KLK3? -- Diagnostic Significance -- Prostate Cancer Prognosis -- Ovarian Cancer -- KLK6, KLK10, and Other KLK Family Members as Promising Markers in Ovarian Cancer Diagnosis -- KLKs with Potential Prognostic and/or Predictive Value in Ovarian Cancer -- Breast Cancer -- KLKs with Diagnostic Significance for Breast Cancer -- Prognosis and Treatment Monitoring -- Endometrial and Cervical Cancer -- KLKs with Potential Clinical Utility in Endometrial Carcinomas -- KLKs with Potential Clinical Utility in Cervical Cancer -- Renal Cell Carcinoma and Urinary Bladder Cancer -- KLKs with Potential Clinical

Utility in RCC and Bladder Cancer -- Gastric and Colon Cancer -- KLKs with Potential Clinical Utility in Gastric Cancer -- KLKs with Potential Clinical Utility in Colon Cancer -- Other Types of Human Cancer -- KLK-Targeting MicroRNAs: A New Era in Cancer Research Has Just Begun -- Single-Nucleotide Polymorphisms (SNPs) in the Human KLK Locus -- Methodologies and Analytical Techniques -- Potential Applications of KLK Family Members to Prognosis, Nonmalignant Diseases, or Conditions -- KLKs and CNS Disorders -- KLKs in Skin Disorders -- Conclusions -- Summary Points -- References -- 7
 MAP17 as Biomarker for Cancer Treatment -- Key Facts. Definitions of Words and Terms -- Introduction -- MAP17 (PDZK1IP1) -- MAP17 in Human Tumors -- Oncogenic Activity of MAP17 -- Potential Applications to Prognosis, Diagnosis, or Response to Therapy -- Summary Points -- References -- 8
 CA 19-9 as a Serum Biomarker in Cancer -- Definitions of Words and Terms -- Introduction -- CA 19-9 Measurement Methodology -- CA 19-9 and Its Utility in Pancreatic Cancer -- Epidemiology of Pancreas Cancer -- CA 19-9 Level as a Diagnostic Marker/Screening Tool in Pancreatic Cancer -- CA 19-9 Level as a Prognostic Marker in Resectable Pancreatic Adenocarcinoma -- CA 19-9 Level as a Prognostic Marker in Advanced and Metastatic Pancreatic Adenocarcinoma -- CA 19-9 in Intraductal Papillary Mucinous Neoplasms of the Pancreas -- CA 19-9 in Gastric Cancer -- CA 19-9 in Biliary Tract Cancers -- CA 19-9 in Colorectal Cancer -- CA 19-9 in Ovarian Cancer -- Utility in Other Malignancies -- CA 19-9 in Occult Primary -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 9
 PTTG (Securin) as Cancer Biomarker -- Key Facts of Pituitary Gland -- Definitions of Words and Terms -- Introduction -- Discovery of the Pituitary Tumor Transforming Gene -- PTTG in Cancer -- PTTG Is an Oncogene -- Basic Molecular PTTG Functions in Cancer not Restricted to Pituitary Adenomas -- Role in Genetic Instability -- Role as a Broad Regulator of the Transcriptome -- Motility, Invasion, and Metastasis -- Epidermal to Mesenchymal Transition -- Clinical Impact of PTTG -- PTTG as a Prognostic Marker -- Cellular Proliferation -- Vascular Proliferation -- Migratory Ability of Tumor Cells -- Perspectives for a Prognostic Application of PTTG in Clinical Practice -- Therapeutic Aspects -- Concluding Remarks -- Summary Points -- References -- 10
 U2 Small Nuclear RNA as a Biomarker in Cancer. Key Facts of Noncoding RNAs as Biomarkers -- Definition of Words and Terms -- Introduction -- U2 snRNA and the Splicing Process of Pre-mRNAs -- Genomic Organization and Sequence Characteristics of U2 snRNA -- RNU2-1 Fragment Biogenesis and Stability -- RNU2-1f in Serum of Pancreatic and Colorectal Cancer Patients -- RNU2-1f in Lung Cancer -- RNU2-1f as Biomarker in Other Cancer Types -- Potential Applications of RNU2-1f Tests to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- Part II: Bladder, Kidney, Liver and Lung -- 11
 Centrosome Amplification as Biomarkers in Bladder Cancer Using Touch Biopsy and Bladder Washing Cytological Specimens -- Key Facts of Centrosome Amplification -- Definitions of Words and Terms -- Introduction -- Mechanism of Centrosome Amplification -- Copy Number Aberrations and Centrosome Amplification -- Clinical Significance of Centrosome Amplification -- Other Biomarkers Using Urine (Bladder Washing Cytology) -- Potential Applications to Prognosis -- Conclusion -- Summary Points -- References -- 12
 Microarrays and Renal Cell Cancer Biomarkers -- Key Facts of Renal Cell Carcinoma -- Definitions of Words and Terms -- Introduction -- Genomic Approaches -- Array-Based CGH (aCGH) and SNP Arrays for Tracking Potential Chromosomal and Gene Marker Loci

-- DNA Methylation Arrays for Unmasking Silenced RCC Markers -- Transcriptomic Approaches -- DNA Microarrays for Screening RCC-Specific Marker Expression Patterns -- miRNA Microarrays for Identifying RCC Key Players of Gene Regulation -- Proteomic Approaches -- Tissue Microarrays (TMA) for Evaluating Molecular Markers with Clinical Relevance in RCC -- Combinations of Microarray Platforms Used to Validate Potential Biomarkers in RCC -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References.

13 Immunogenic Cell Death Markers in Liver Cancer.

Sommario/riassunto

The World Health Organisation have reported that each year on a global basis there are over 8 million deaths from cancer. This is 13% of all deaths. As well as those who die, there are many who are being treated for cancer. Some cancers, hitherto deemed to be incurable, can now be cured. Part of the overall package of healthcare related to cancer is the application of biomarkers. Biomarkers can be used not only to determine stages and effects of cancer, but also to aid treatments regimes. Biomarkers in Cancer combines detailed information on cancer types and the use of biological indicators. It covers the latest knowledge, trends and applications. It links conventional approaches with new platforms.
